DCF Advisers’s Aerie Pharmaceuticals AERI Stock Holding History

DCF Advisers’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-157,665	Closed	-$2.38M	–	85
2022 Q3	$2.38M	Sell	157,665 -9,500	-6%	-$110K	1.54%	22
2022 Q2	$1.25M	Sell	167,165 -22,400	-12%	-$158K	0.75%	36
2022 Q1	$1.73M	Sell	189,565 -2,500	-1%	-$19.3K	0.76%	36
2021 Q4	$1.35M	Buy	192,065 +55,564	+41%	+$581K	0.55%	41
2021 Q3	$1.56M	Buy	136,501 +45,201	+50%	+$661K	0.69%	38
2021 Q2	$1.46M	Sell	91,300 -1,200	-1%	-$20.6K	0.52%	40
2021 Q1	$1.65M	Buy	92,500 +57,500	+164%	+$993K	0.72%	37
2020 Q4	$473K	Buy	+35,000	New	+$423K	0.2%	69
2020 Q1	–	Sell	-20,500	Closed	-$495K	–	88
2019 Q4	$495K	Buy	+20,500	New	+$425K	0.31%	55

DCF Advisers's AERI Position: Q4 2022 in Review

DCF Advisers sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 157,665 shares — an estimated $2.38M sold.

DCF Advisers first reported a position in AERI in Q4 2019 and held it in 9 quarters. The position peaked at $2.38M in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

DCF Advisers reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
DCF Advisers sold 157,665 Aerie Pharmaceuticals shares in Q4 2022, an estimated $2.38M.
DCF Advisers first reported a position in Aerie Pharmaceuticals in Q4 2019 and held it in 9 quarters.
DCF Advisers's Aerie Pharmaceuticals position peaked at $2.38M in Q3 2022.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on DCF Advisers's 13F filing for Q4 2022, filed 13 Feb 2023.